Answers are grounded in this paper and cite their sources.
Case series shows adalimumab improves outcomes in patients with refractory acute sympathetic ophthalmia, suggesting effective treatment.
We report a case series of three patients with SO refractory to pulse steroids and IMT, which showed rapid anatomical and functional improvement with ADA. ADA is highly efficacious in acute refractory SO, resulting in prompt resolution of active inflammation and maintenance of remission. This case series adds to the limited existing evidence on the role of TNF-α inhibitors in managing this rare but sight-threatening condition.
No takes yet. Share an insight, caveat, or question.
Narain et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: